Literature DB >> 23674871

Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis.

Lian-Zhen Yu1, Hai-Yang Wang, Shu-Ping Yang, Zhi-Ping Yuan, Fang-Yuan Xu, Chao Sun, Rui-Hua Shi.   

Abstract

AIM: To investigate the expression of interleukin (IL)-22 and its related proteins in biopsy specimens from patients with ulcerative colitis (UC) and UC-related carcinogenesis.
METHODS: Biopsy specimens were obtained from patients with inactive (n = 10), mild-to-moderately active (n = 30), severely active (n = 34), initial (n = 30), and chronic UC (n = 44), as well as UC patients with dysplasia (n = 10). Specimens from patients without colonic abnormalities (n = 20) served as controls. Chronic colitis in experimental mice was induced by 2.5% dextran sodium sulfate. The expression levels of IL-22, IL-23, IL-22R1 and phosphorylated STAT3 (p-STAT3) were determined by immunohistochemistry. Bcl-2, cyclin D1 and survivin expression was detected by Western blotting.
RESULTS: Patients with active UC had significantly more IL-22, IL-23, IL-22R1 and p-STAT3-positive cells than the patients with inactive UC and normal controls. Furthermore, IL-22 and related proteins were closely related to the severity of the colitis. The expression of IL-22 and IL-22R1 in the tissue of initial UC was stronger than in that of chronic UC, whereas the expression of p-STAT3 was significantly increased in chronic UC tissues. In dysplasia tissues, the expression level of IL-22 and related proteins was higher compared with controls. Mouse colitis model showed that expression of IL-22, IL-22R1 and IL-23 was increased with time, p-STAT3 and the downstream gene were also remarkably upregulated.
CONCLUSION: IL-22/STAT3 signaling pathway may be related to UC and UC-induced carcinogenesis and IL-22 can be used as a biomarker in judging the severity of UC.

Entities:  

Keywords:  Interleukin-22; Interleukin-22R1; STAT3; Ulcerative colitis; Ulcerative colitis-related carcinogenesis

Mesh:

Substances:

Year:  2013        PMID: 23674871      PMCID: PMC3645382          DOI: 10.3748/wjg.v19.i17.2638

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  38 in total

1.  STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice.

Authors:  Mi-La Cho; Jung-Won Kang; Young-Mee Moon; Hyo-Jung Nam; Joo-Yeon Jhun; Seong-Beom Heo; Hyun-Tak Jin; So-Youn Min; Ji-Hyeon Ju; Kyung-Su Park; Young-Gyu Cho; Chong-Hyeon Yoon; Sung-Hwan Park; Young-Chul Sung; Ho-Youn Kim
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

2.  Autophagic cell death of pancreatic acinar cells in serine protease inhibitor Kazal type 3-deficient mice.

Authors:  Masaki Ohmuraya; Masahiko Hirota; Masatake Araki; Noboru Mizushima; Makoto Matsui; Takao Mizumoto; Kyoko Haruna; Shoen Kume; Motohiro Takeya; Michio Ogawa; Kimi Araki; Ken-Ichi Yamamura
Journal:  Gastroenterology       Date:  2005-08       Impact factor: 22.682

3.  Cutting edge: immune cells as sources and targets of the IL-10 family members?

Authors:  Kerstin Wolk; Stefanie Kunz; Khusru Asadullah; Robert Sabat
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

4.  IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration.

Authors:  Stephan Brand; Florian Beigel; Torsten Olszak; Kathrin Zitzmann; Sören T Eichhorst; Jan-Michel Otte; Helmut Diepolder; Andreas Marquardt; Wolfgang Jagla; Andreas Popp; Stéphane Leclair; Karin Herrmann; Julia Seiderer; Thomas Ochsenkühn; Burkhard Göke; Christoph J Auernhammer; Julia Dambacher
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2006-04       Impact factor: 4.052

Review 5.  IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues.

Authors:  Austin L Gurney
Journal:  Int Immunopharmacol       Date:  2004-05       Impact factor: 4.932

6.  Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells.

Authors:  Marehalli L Nagalakshmi; Anne Rascle; Sandra Zurawski; Satish Menon; Rene de Waal Malefyt
Journal:  Int Immunopharmacol       Date:  2004-05       Impact factor: 4.932

7.  IL-22 increases the innate immunity of tissues.

Authors:  Kerstin Wolk; Stefanie Kunz; Ellen Witte; Markus Friedrich; Khusru Asadullah; Robert Sabat
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

8.  Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis.

Authors:  Lei Zhang; Yong-gang Li; Yu-hua Li; Lei Qi; Xin-guang Liu; Cun-zhong Yuan; Nai-wen Hu; Dao-xin Ma; Zhen-feng Li; Qiang Yang; Wei Li; Jian-min Li
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

9.  Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis.

Authors:  Jenny Jongstra-Bilen; Mehran Haidari; Su-Ning Zhu; Mian Chen; Daipayan Guha; Myron I Cybulsky
Journal:  J Exp Med       Date:  2006-08-07       Impact factor: 14.307

10.  IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.

Authors:  Jason R Chan; Wendy Blumenschein; Erin Murphy; Caroline Diveu; Maria Wiekowski; Susan Abbondanzo; Linda Lucian; Richard Geissler; Scott Brodie; Alexa B Kimball; Daniel M Gorman; Kathleen Smith; Rene de Waal Malefyt; Robert A Kastelein; Terrill K McClanahan; Edward P Bowman
Journal:  J Exp Med       Date:  2006-10-30       Impact factor: 14.307

View more
  19 in total

Review 1.  Recent advancement in understanding colitis-associated tumorigenesis.

Authors:  Daren Low; Mari Mino-Kenudson; Emiko Mizoguchi
Journal:  Inflamm Bowel Dis       Date:  2014-11       Impact factor: 5.325

2.  IL-22 promotes the migration and invasion of gastric cancer cells via IL-22R1/AKT/MMP-9 signaling.

Authors:  Yinghua Ji; Xiaoyu Yang; Jinsong Li; Zhihong Lu; Xiaorui Li; Jian Yu; Na Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 3.  Biological and pathological activities of interleukin-22.

Authors:  Mirna Perusina Lanfranca; Yanwei Lin; Jingyuan Fang; Weiping Zou; Timothy Frankel
Journal:  J Mol Med (Berl)       Date:  2016-02-29       Impact factor: 4.599

Review 4.  Targeting interleukins for the treatment of inflammatory bowel disease-what lies beyond anti-TNF therapy?

Authors:  Mairi H McLean; Markus F Neurath; Scott K Durum
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

Review 5.  Genomic and molecular alterations in human inflammatory bowel disease-associated colorectal cancer.

Authors:  Marie Muller; Franck Hansmannel; Djesia Arnone; Myriam Choukour; Ndeye Coumba Ndiaye; Tunay Kokten; Rémi Houlgatte; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2020-04-08       Impact factor: 4.623

Review 6.  Environmental triggers in IBD: a review of progress and evidence.

Authors:  Ashwin N Ananthakrishnan; Charles N Bernstein; Dimitrios Iliopoulos; Andrew Macpherson; Markus F Neurath; Raja A Raja Ali; Stephan R Vavricka; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-10-11       Impact factor: 46.802

7.  Th22 cell accumulation is associated with colorectal cancer development.

Authors:  Yong-Hong Huang; Yun-Fei Cao; Zhi-Yuan Jiang; Sen Zhang; Feng Gao
Journal:  World J Gastroenterol       Date:  2015-04-14       Impact factor: 5.742

Review 8.  Targeting IL-10 Family Cytokines for the Treatment of Human Diseases.

Authors:  Xiaoting Wang; Kit Wong; Wenjun Ouyang; Sascha Rutz
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-02-01       Impact factor: 10.005

Review 9.  STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer.

Authors:  Andrew V Nguyen; Yuan-Yuan Wu; Elaine Y Lin
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

10.  Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling.

Authors:  Danfeng Sun; Yanwei Lin; Jie Hong; Haoyan Chen; Nisha Nagarsheth; Dongjun Peng; Shuang Wei; Emina Huang; Jingyuan Fang; Ilona Kryczek; Weiping Zou
Journal:  Oncoimmunology       Date:  2015-09-02       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.